RNAC
NASDAQ HealthcareCartesian Therapeutics, Inc. - Common Stock
Biotechnology
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
๐ Market Data
| Price | $6.22 |
|---|---|
| Volume | 204,605 |
| Market Cap | 182.26M |
| RSI (14-Day) | 54.2 |
| 200-Day MA | $8.39 |
| 50-Day MA | $6.86 |
| 52-Week High | $15.57 |
| 52-Week Low | $5.60 |
| Forward P/E | -3.68 |
| Price / Book | -1.28 |
๐ฏ Investment Strategy Scores
RNAC scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (89/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find RNAC in your text
Paste any article, transcript, or post โ the tool will extract RNAC and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.